实现欧洲Respirato TY -的T1 -ry Roadmap: halfway there? JF - European Respiratory Journal JO - Eur Respir J SP - 1127 LP - 1129 DO - 10.1183/09031936.00152814 VL - 44 IS - 5 AU - Kamel, Nadia Y1 - 2014/11/01 UR - //www.qdcxjkg.com/content/44/5/1127.abstract N2 - Soon 5 years will have passed since the European Respiratory Society (ERS) pronounced its 10-year vision for respiratory medicine with the launch of the European Respiratory Roadmap. With regards to research, the following was stated: “There is a great need to find new, effective ways for collaboration between academic research and innovators, in order to develop better medicines and improved diagnostic methods. A significant problem is the real deficiency of new innovative medicines in the respiratory field, as only nine new therapies have been developed over the past 40 years” [1]. We are swiftly approaching the halfway mark for the 10-year vision set out when the Roadmap was launched, and it is time to assess to what degree policies have changed since then, and identify those areas that merit further efforts by stakeholders to achieve a better environment for better medicines. Two relevant developments have been: 1) the overhaul of the European legislation that governs the conduct of clinical trials in Europe; and 2) our strong involvement in the activities of the Alliance for Biomedical Research in Europe, which recently advocated for radical change in the way the health research priorities are set in the framework of Horizon 2020, the 7-year European Union ER -